Get Premium to unlock powerful stock data
NAS:SUPN (USA)  
Supernus Pharmaceuticals Inc logo

Supernus Pharmaceuticals Inc

$ 29.35 +0.43 (+1.49%) 08:08 PM EST
On watch
P/E:
22.58
P/B:
1.89
Market Cap:
$ 1.57B
Enterprise V:
$ 1.70B
Volume:
327.01K
Avg Vol (2M):
401.78K
Also Trade In:
Volume:
327.01K
Market Cap $:
1.57B
PE Ratio:
22.58
Avg Vol (2-Month):
401.78K
Enterprise Value $:
1.70B
PB Ratio:
1.89
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Supernus Pharmaceuticals Inc
NAICS : 325412 SIC : 2834
9715 Key West Avenue, Rockville, MD, USA, 20850
Description
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The company products include Oxtellar XR, Trokendi XR, SPN-812, and others. The majority of the revenue is generated from the sale of Trokendi XR.
Name Current Vs Industry Vs History
Cash-To-Debt 0.7
Equity-to-Asset 0.51
Debt-to-Equity 0.54
Debt-to-EBITDA 3.11
Interest Coverage 3.52
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.31
Distress
Grey
Safe
Beneish M-Score -2.52
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 75.03
9-Day RSI 66.38
14-Day RSI 60.5
6-1 Month Momentum % -4.05
12-1 Month Momentum % -10.86

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2
Quick Ratio 1.69
Cash Ratio 1.1
Days Inventory 321.34
Days Sales Outstanding 84.02
Days Payable 41.12

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -0.6

Financials (Next Earnings Date:2022-08-04 Est.)

SUPN's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:SUPN

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 601.349
EPS (TTM) ($) 1.3
Beta 1.1
Volatility % 26.38
14-Day RSI 60.5
14-Day ATR ($) 1.037169
20-Day SMA ($) 27.9135
12-1 Month Momentum % -10.86
52-Week Range ($) 23.15 - 34.5
Shares Outstanding (Mil) 53.41

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Supernus Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More